Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US

Abstract Background Patients with infantile-onset spinal muscular atrophy (SMA), a rare, genetic neuromuscular disease, do not achieve key motor function milestones (e.g., sitting) and have short life expectancy in the absence of treatment. Nusinersen is a disease-modifying therapy for patients with...

Full description

Bibliographic Details
Main Authors: Praveen Thokala, Matt Stevenson, Varun M. Kumar, Shijie Ren, Alexandra G. Ellis, Richard H. Chapman
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Cost-effectiveness
Spinal muscular atrophy (SMA)
Nusinersen
Online Access:http://link.springer.com/article/10.1186/s12962-020-00234-8

Internet

http://link.springer.com/article/10.1186/s12962-020-00234-8

Similar Items